CoLucid Pharmaceuticals, a biotech developing therapies for migraine headaches, announced terms for its IPO on Monday.
The Burlington, MA-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, CoLucid Pharmaceuticals would command a market value of $215 million.
CoLucid Pharmaceuticals, which was founded in 2005, plans to list on the NASDAQ under the symbol CLCD. Piper Jaffray and Stifel are the joint bookrunners on the deal. It is expected to price during the week of April 27, 2015.
